Kenvue Inc. $KVUE Shares Sold by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 61.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 18,092 shares of the company’s stock after selling 29,197 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Kenvue were worth $294,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Cornerstone Planning Group LLC increased its holdings in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the last quarter. NBT Bank N A NY grew its position in shares of Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of Kenvue in the third quarter worth $25,000. Golden State Wealth Management LLC raised its holdings in Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares in the last quarter. Finally, Trust Co. of Vermont boosted its stake in Kenvue by 50.9% during the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $18.12 on Monday. The company has a market cap of $34.72 billion, a P/E ratio of 24.16 and a beta of 0.59. The business has a 50 day moving average of $17.24 and a two-hundred day moving average of $17.83. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 110.67%.

Insider Buying and Selling

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of the company’s stock in a transaction on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.17% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KVUE shares. Barclays boosted their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on Kenvue in a report on Friday, October 24th. Evercore set a $18.00 target price on Kenvue in a report on Tuesday, October 28th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Finally, Johnson Rice reissued a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Four research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $19.46.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.